According to Vertex Pharmaceuticals's latest financial reports the company's current earnings (TTM) are $4.42 B. an increase over its 2022 earnings that were of $4.28 B.The earnings displayed on this page is the company's Pretax Income.
Year | Earnings | Change |
---|---|---|
2023 | $4.42 B | 3.19% |
2022 | $4.28 B | 53.56% |
2021 | $2.79 B | -12.06% |
2020 | $3.17 B | 118.45% |
2019 | $1.45 B | 120.64% |
2018 | $0.65 B | 1473.64% |
2017 | $41.86 M | 197.6% |
2016 | $14.06 M | -102.97% |
2015 | -$0.48 B | -28.46% |
2014 | -$0.67 B | -51.5% |
2013 | -$1.37 B | -30584.68% |
2012 | $4.47 M | -95.47% |
2011 | $98.89 M | |
2009 | -$0.6 B | |
2007 | -$0.42 B | 83.1% |
2006 | -$0.23 B | 59.02% |
2005 | -$0.15 B | 3.28% |
2004 | -$0.14 B | -38.16% |
2003 | -$0.23 B |
Company | Earnings | Earnings differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | $16.97 B | 283.64% | ๐บ๐ธ USA |
AbbVie ABBV | $6.25 B | 41.28% | ๐บ๐ธ USA |
Gilead Sciences GILD | $6.85 B | 55.04% | ๐บ๐ธ USA |
Merck MRK | $3.03 B | -31.40% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | $8.44 B | 90.78% | ๐บ๐ธ USA |
Enanta Pharmaceuticals
ENTA | -$0.13 B | -102.92% | ๐บ๐ธ USA |